High-Risk Beta
This platform is experimental. Smart contracts are unaudited. Use at your own risk.
NPR focuses on transformed and addiction, with context pulled from source reporting instead of recycled feed copy.
What happened: A large study found that people taking GLP-1 drugs like Ozempic for diabetes were less likely to be diagnosed with substance use disorder.
What to watch next: movement around transformed, addiction.
Verbatim descriptions from source feeds — unedited, as received
NPR(lean-left)
A large study found that people taking GLP-1 drugs like Ozempic for diabetes were less likely to be diagnosed with substance use disorder.
Read full original ›The Hill(center)
The U.S. Food and Drug Administration (FDA) has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications, popularly known as Ozempic and Wegovy. The FDA wrote in a March 5 letter that it observed “serious vi
Read full original ›Bloomberg(center)
Eli Lilly & Co. shares tumbled after HSBC turned bearish on the stock, for the second time in a year, saying investor expectations for weight-loss drugs are overinflated.
Read full original ›3 sources · 3 evidence links
Swarm Claim
FDA sends warning letter to Novo Nordisk over failure to report deaths, adverse side effects of GLP-1s.
NPR · link
GLP-1s have transformed weight loss and diabetes. Is addiction next?A large study found that people taking GLP-1 drugs like Ozempic for diabetes were less likely to be diagnosed with substance use disorder.
The Hill · report
FDA sends warning letter to Novo Nordisk over failure to report deaths, adverse side effects of GLP-1sThe U.S. Food and Drug Administration (FDA) has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications, popularly known as Ozempic and Wegovy. The FDA wrote in a March 5 letter that it observed “serious vi
Bloomberg · link
Lilly Gets Lone Sell From HSBC Ahead of Deeper Weight Loss Drug Price CutsEli Lilly & Co. shares tumbled after HSBC turned bearish on the stock, for the second time in a year, saying investor expectations for weight-loss drugs are overinflated.
The U.S. Food and Drug Administration (FDA) has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications, popularly known as Ozempic and Wegovy. The FDA wrote in a March 5 letter that it observed “serious vi
Eli Lilly & Co. shares tumbled after HSBC turned bearish on the stock, for the second time in a year, saying investor expectations for weight-loss drugs are overinflated.
2 archived stories related to this coverage
The U.S. Food and Drug Administration (FDA) has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications, popularly known as Ozempic and Wegovy. The FDA wrote in a March 5 letter that it observed “serious vi
Politics · archivedEli Lilly & Co. shares tumbled after HSBC turned bearish on the stock, for the second time in a year, saying investor expectations for weight-loss drugs are overinflated.
Business · archivedConnect your wallet to join the discussion.
No comments yet. Be the first to share your take.